Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units.


Journal

JAMA pediatrics
ISSN: 2168-6211
Titre abrégé: JAMA Pediatr
Pays: United States
ID NLM: 101589544

Informations de publication

Date de publication:
01 Sep 2020
Historique:
pubmed: 12 5 2020
medline: 13 11 2020
entrez: 12 5 2020
Statut: ppublish

Résumé

The recent and ongoing coronavirus disease 2019 (COVID-19) pandemic has taken an unprecedented toll on adults critically ill with COVID-19 infection. While there is evidence that the burden of COVID-19 infection in hospitalized children is lesser than in their adult counterparts, to date, there are only limited reports describing COVID-19 in pediatric intensive care units (PICUs). To provide an early description and characterization of COVID-19 infection in North American PICUs, focusing on mode of presentation, presence of comorbidities, severity of disease, therapeutic interventions, clinical trajectory, and early outcomes. This cross-sectional study included children positive for COVID-19 admitted to 46 North American PICUs between March 14 and April 3, 2020. with follow-up to April 10, 2020. Prehospital characteristics, clinical trajectory, and hospital outcomes of children admitted to PICUs with confirmed COVID-19 infection. Of the 48 children with COVID-19 admitted to participating PICUs, 25 (52%) were male, and the median (range) age was 13 (4.2-16.6) years. Forty patients (83%) had significant preexisting comorbidities; 35 (73%) presented with respiratory symptoms and 18 (38%) required invasive ventilation. Eleven patients (23%) had failure of 2 or more organ systems. Extracorporeal membrane oxygenation was required for 1 patient (2%). Targeted therapies were used in 28 patients (61%), with hydroxychloroquine being the most commonly used agent either alone (11 patients) or in combination (10 patients). At the completion of the follow-up period, 2 patients (4%) had died and 15 (31%) were still hospitalized, with 3 still requiring ventilatory support and 1 receiving extracorporeal membrane oxygenation. The median (range) PICU and hospital lengths of stay for those who had been discharged were 5 (3-9) days and 7 (4-13) days, respectively. This early report describes the burden of COVID-19 infection in North American PICUs and confirms that severe illness in children is significant but far less frequent than in adults. Prehospital comorbidities appear to be an important factor in children. These preliminary observations provide an important platform for larger and more extensive studies of children with COVID-19 infection.

Identifiants

pubmed: 32392288
pii: 2766037
doi: 10.1001/jamapediatrics.2020.1948
pmc: PMC7489842
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

868-873

Commentaires et corrections

Type : CommentIn

Références

JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Med Virol. 2020 Oct;92(10):1787-1788
pubmed: 32297987
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426
pubmed: 32271728
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
Curr Med Chem. 2020;27(27):4536-4541
pubmed: 32297571
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
Clin Med (Lond). 2020 Apr 17;:
pubmed: 32303497

Auteurs

Lara S Shekerdemian (LS)

Texas Children's Hospital, Baylor College of Medicine, Houston.

Nabihah R Mahmood (NR)

Children's Healthcare of Atlanta, Atlanta, Georgia.

Katie K Wolfe (KK)

Ann and Robert H. Lurie Children's Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Becky J Riggs (BJ)

Johns Hopkins Children's Center, Johns Hopkins School of Medicine, Baltimore, Maryland.

Catherine E Ross (CE)

Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.

Christine A McKiernan (CA)

Baystate Children's Hospital, UMass Medical School Baystate Campus, Springfield, Massachusetts.

Sabrina M Heidemann (SM)

Children's Hospital of Michigan, Wayne State University, Detroit.

Lawrence C Kleinman (LC)

Bristol-Myers Squibb Hospital, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey.

Anita I Sen (AI)

NewYork-Presbyterian Morgan Stanley Children's Hospital, Columbia University Medical Center, New York.

Mark W Hall (MW)

Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus.

Margaret A Priestley (MA)

Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia.

John K McGuire (JK)

Seattle Children's Hospital, University of Washington, Seattle.

Konstantinos Boukas (K)

Children's Memorial Hermann Hospital, University of Texas, Houston.

Matthew P Sharron (MP)

Children's National Medical Center, George Washington School of Medicine, Washington, DC.

Jeffrey P Burns (JP)

Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH